文献速递艾滋病与性传播感染病毒性肝炎

澳大利亚HIV感染者丙肝微消除进展:CEASE研究

Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.
PubMed 文献 · Clin Infect Dis · 2020-01-01

CEASE前瞻性队列研究纳入澳大利亚14家诊所的402例HIV/HCV抗体阳性成人,评估全员DAA治疗可及后的消除进展。2016年DAA可及后治疗 uptake 升至80%,至2018年累计治疗率达91%,HCV病毒血症患病率从2014年82%降至2018年8%,再感染率仅0.81/100人年。

要点

  • 全员DAA可及后HIV/HCV共感染者年治疗率从7%-11%升至80%
  • 2018年HCV病毒血症患病率降至8%(95%CI 6-12%)
  • 再感染率低(0.81/100人年),支持微消除可行性

核心结论

  • 澳大利亚无限制DAA治疗的高 uptake 和有效性使治疗快速扩大,HCV感染负担大幅下降且再感染率低,提示HIV感染者中HCV微消除可行。

研究设计与样本

  • CEASE前瞻性队列研究,2014年7月至2017年3月从澳大利亚14家初级和三级诊所纳入402例HIV/HCV抗体阳性成人,不论病毒血症状态,随访至2018年5月(中位随访2.63年)。

主要发现

  • DAA可及后,符合条件者年HCV治疗 uptake 从2014年7%和2015年11%升至2016年80%。
  • 至2018年,曾符合治疗条件者累计HCV治疗 uptake 为91%(336/371)。
  • HCV病毒血症患病率从2014年82%(95%CI 78-86%)降至2018年8%(95%CI 6-12%)。
  • 仅5例报告再感染,再感染发生率为0.81/100人年(95%CI 0.34-1.94)。

临床怎么用

  • 在HIV感染者中推行无限制DAA治疗可快速扩大丙肝治疗覆盖并大幅降低病毒血症负担。
  • 治疗后再感染率低,支持在HIV/HCV共感染人群中推进微消除策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microelimination of hepatitis C virus (HCV) among people living with human immunodeficiency virus (HIV) may be feasible in Australia, given unrestricted access to direct-acting antiviral (DAA) therapy from 2016. Our aim was to evaluate progress towards elimination goals within HIV/HCV-coinfected adults in Australia following universal DAA access. METHODS: The CEASE prospective cohort study enrolled adults with HIV/HCV, irrespective of viremic status, from 14 primary and tertiary clinics in Australia. Annual and cumulative HCV treatment uptake, outcome, and HCV RNA prevalence were evaluated, with follow-up through May 2018 (median follow-up, 2.63 years). Factors associated with DAA uptake were analyzed. RESULTS: Between July 2014 and March 2017, 402 participants who were HIV/HCV antibody positive were enrolled (95% male [80% gay and bisexual men,], 13% cirrhosis, 80% history of injecting drug use [39% currently injecting]). Following universal DAA access, annual HCV treatment uptake in those eligible increased from 7% and 11% per year in 2014 and 2015, respectively, to 80% in 2016. By 2018, cumulative HCV treatment uptake in those ever eligible for treatment was 91% (336/371). HCV viremic prevalence declined from 82% (95% CI, 78-86%) in 2014 to 8% (95% CI, 6-12%) in 2018. Reinfection was reported in only 5 participants for a reinfection incidence of 0.81 per 100 person-years (95% CI, 0.34-1.94). CONCLUSIONS: High uptake and effectiveness of unrestricted DAA therapy in Australia have permitted rapid treatment scale-up, with a dramatic reduction in HCV infection burden and low reinfection rate among people living with HIV, suggesting that microelimination is feasible. CLINICAL TRIALS REGISTRATION: NCT02102451.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Martinello M, Yee J, Bartlett SR, et al. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clin Infect Dis. 2020. PMID: 31585005. doi:10.1093/cid/ciz985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。